Literature DB >> 19597028

Risk of bilateral renal cell cancer.

Fredrik Wiklund1, Steinar Tretli, Toni K Choueiri, Sabina Signoretti, Katja Fall, Hans-Olov Adami.   

Abstract

PURPOSE: The risk of developing bilateral kidney cancer has not been adequately defined in any large, population-based study with long-term follow-up to our knowledge. PATIENTS AND METHODS: We estimated the risk of metachronous bilateral renal cell cancer in patients diagnosed with unilateral kidney cancer, as recorded in the nationwide cancer registries of Norway and Sweden. Altogether 28,642 patients were followed for an average of 4.4 years. The standardized incidence ratio--the ratio of the observed number of bilateral cancers to the number expected on the basis of the incidence in the Norwegian and Swedish population at large--was used as a measure of relative risk. We used multivariate Poisson regression to separate the effects of the explanatory variables.
RESULTS: A synchronous bilateral renal cell cancer was reported in 86 patients. A total of 112 metachronous bilateral cancers were recorded during 126,493 person-years of follow-up compared with 35.8 expected, yielding an overall relative risk (RR) of 3.1 (95% CI, 2.6 to 3.8) and a cumulative incidence of 0.8% after 20 or more years of follow-up. In the multivariate analyses, risk increased monotonically with younger age at first diagnosis (P for trend < .001); compared with patients who were 60 years or older, those younger than 40 years were at a 17-fold higher risk (RR = 17.4; 95% CI, 10.1 to 29.8). We also found a modest but statistically significant decreasing trend with increasing duration of follow-up.
CONCLUSION: The risk of metachronous bilateral renal cell cancer is drastically higher among patients first affected at a young age, suggesting a subset of early onset renal cell cancer with a strong genetic component.

Entities:  

Mesh:

Year:  2009        PMID: 19597028     DOI: 10.1200/JCO.2008.20.6524

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  16 in total

1.  The impact of germline BHD mutation on histological concordance and clinical treatment of patients with bilateral renal masses and known unilateral oncocytoma.

Authors:  Ronald S Boris; Jihane Benhammou; Maria Merino; Peter A Pinto; W Marston Linehan; Gennady Bratslavsky
Journal:  J Urol       Date:  2011-04-15       Impact factor: 7.450

Review 2.  Epidemiology and risk factors for kidney cancer.

Authors:  Wong-Ho Chow; Linda M Dong; Susan S Devesa
Journal:  Nat Rev Urol       Date:  2010-05       Impact factor: 14.432

3.  Outcomes of synchronous and metachronous bilateral small renal masses (< 4 cm): a population-based cohort study.

Authors:  Nissar Ahmed Sheikh; Mohammed Hassan Khan; Sanjay Pillai; Stephen Lang; Ghulam Nabi
Journal:  Int Urol Nephrol       Date:  2018-02-10       Impact factor: 2.370

Review 4.  Renal cell carcinoma.

Authors:  Paul Cairns
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

Review 5.  Use of Kidneys with Small Renal Tumors for Transplantation.

Authors:  Alejandro Lugo-Baruqui; Giselle Guerra; Adriana Arocha; George W Burke; Gaetano Ciancio
Journal:  Curr Urol Rep       Date:  2016-01       Impact factor: 3.092

6.  Genetic basis of bilateral renal cancer: implications for evaluation and management.

Authors:  W Marston Linehan
Journal:  J Clin Oncol       Date:  2009-07-13       Impact factor: 44.544

7.  Differential VHL Mutation Patterns in Bilateral Clear Cell RCC Distinguishes Between Independent Primary Tumors and Contralateral Metastatic Disease.

Authors:  Cathy D Vocke; Christopher J Ricketts; Adam R Metwalli; Peter A Pinto; Rabindra Gautam; Mark Raffeld; Maria J Merino; Mark W Ball; W Marston Linehan
Journal:  Urology       Date:  2022-04-23       Impact factor: 2.633

8.  Evaluation of functional outcome of bilateral kidney tumors after sequential surgery.

Authors:  Jung Kwon Kim; Hwanik Kim; Hakmin Lee; Jong Jin Oh; Sangchul Lee; Sung Kyu Hong; Cheol Kwak; Seok-Soo Byun
Journal:  BMC Cancer       Date:  2021-05-24       Impact factor: 4.430

9.  High ERα36 Expression Level and Membrane Location Predict Poor Prognosis in Renal Cell Carcinoma.

Authors:  Qiang Wang; Wei Zhang; Jing Yang; Yu-Lin Liu; Ze-Xuan Yan; Zheng-Jun Guo; Yu-Jun Li; Xiu-Wu Bian
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

Review 10.  Treatment of patients with metastatic renal cell carcinoma undergoing hemodialysis: case report of two patients and short literature review.

Authors:  John Syrios; Georgios Kechagias; Nicolas Tsavaris
Journal:  BMC Nephrol       Date:  2013-04-12       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.